Anaptysbio: Pay

Anaptysbio paid its 3 named executives $10.5M in total in FY2025 (Jun). CEO Daniel Faga was paid $6.1M of that.

Pay$100 in the stock at the end of FY21 → $86
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Daniel FagaPresident and Chief Executive Officer and Director
FY2025 (Jun)
FY2024 (Jun)
FY2023 (Jun)
FY2022 (Jun)
4 years
Paul LizzulChief Medical Officer
FY2025 (Jun)
FY2024 (Jun)
FY2023 (Jun)
FY2022 (Jun)
4 years
Dennis MulroyChief Financial Officer
FY2025 (Jun)
FY2024 (Jun)
FY2023 (Jun)
3 years

CEO pay against the pay peers

In FY2025 (Jun), the median CEO pay of the 2 peers with pay on file was $6.6M. The CEO of Anaptysbio was paid $6.1M, 8% below the median.

  1. 1Kymera Therapeutics
  2. 2Anaptysbio
  3. 3Kura Oncology
  4. 4ALX OncologyNot disclosed
  5. 5Allogene TherapeuticsNot disclosed
  6. 6Apogee TherapeuticsNot disclosed
  7. 7ArcellxNot disclosed
  8. 8Astria TherapeuticsNot disclosed
  9. 9Centessa PharmaceuticalsNot disclosed
  10. 10IGM BiosciencesNot disclosed
  11. 11Janux TherapeuticsNot disclosed
  12. 12Jasper TherapeuticsNot disclosed
  13. 13Pilant TherapeuticsNot disclosed
  14. 14Replimune GroupNot disclosed
  15. 15XencorNot disclosed
  16. 16iTeos TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.